Bioymifi

CAS No. 1420071-30-2

Bioymifi( Bioymifi )

Catalog No. M11756 CAS No. 1420071-30-2

Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 38 In Stock
5MG 58 In Stock
10MG 98 In Stock
25MG 203 In Stock
50MG 365 In Stock
100MG 531 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Bioymifi
  • Note
    Research use only, not for human use.
  • Brief Description
    Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis
  • Description
    Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Bioymifi
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    DR5
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1420071-30-2
  • Formula Weight
    494.32
  • Molecular Formula
    C22H12BrN3O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C1NC(C2=C1C=CC(C3=CC=C(/C=C(SC(N4C5=CC=C(Br)C=C5)=N)/C4=O)O3)=C2)=O
  • Chemical Name
    (Z)-5-(5-[(3-[4-Bromophenyl]-2-imino-4-oxothiazolidin-5-ylidene)methyl]furan-2-yl)isoindoline-1,3-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang G, et al. Nat Chem Biol. 2013 Feb;9(2):84-9.
molnova catalog
related products
  • Homovanillyl alcohol

    Homovanillyl alcohol is a biological metabolite of Hydroxytyrosol.?

  • GSK3145095

    GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.

  • Tebentafusp

    Tebentafusp (IMCgp100) is a protein that specifically targets gp100 and consists of a soluble T-cell receptor functionally fused to an anti-CD3 immune effector Tebentafusp has potential anti-tumor activity, induces the production of inflammatory cytokines and cytolytic proteins, and can be used to study unresectable or metastatic uveal melanoma.